METABOLIC-ONLY RESPONSE ASSESSMENT ALLOWS FOR OMISSION OF RESIDUAL NODE RADIATION THERAPY (RNRT) FOR THE MAJORITY OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) WHILE MAINTAINING EXCELLENT EVENT FREE (EFS) AND OVERALL SURVIVAL (OS): A REPORT FROM THE PEDIATRIC HODGKIN CONSORTIUM’S PHASE 2 STUDY cHOD17 (NCT03755804)

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research Pub Date : 2025-09-01 DOI:10.1016/j.leukres.2025.107981

Jamie E. Flerlage, Angela M. Feraco, Yiwang Zhou, Ying Zheng, John T. Lucas Jr, Stephanie B. Dixon, Jessi Rogers Blake, Lindsay Wilemon, Bryan A. Roberts, Lianna J. Marks, Alison M. Friedmann, Shannon MacDonald, Howard J. Weinstein, Pedro de Alarcon, Eric C. Larsen, Torunn I. Yock, Susan Hiniker, Christine Bolen, Stephan D. Voss, Michael P. Link, Matthew J. Ehrhardt

引用次数: 0

查看原文本刊更多论文

儿童霍奇金协会2期研究cHOD17 （NCT03755804）的一份报告显示，仅代谢反应评估允许对大多数经典霍奇金淋巴瘤（cHL）患者省略残余淋巴结放射治疗（RNRT），同时保持良好的无事件（EFS）和总生存期（OS）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia research 医学-血液学

CiteScore

4.00

自引率

3.70%

发文量

259

审稿时长

1 months

期刊介绍： Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.